Drug Pipeline

Povetacicept Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
2
Phase 3
2
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-06 NCT07204275
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With…		 Trial sites expanded: 93 -> 98 locations
2026-05-19 NCT07501702
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis		 Trial sites expanded: 6 -> 9 locations
Active Studies by Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06564142 Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) Immunoglobulin A Nephropathy Active, Not Recruiting
Phase 2/3
NCT07204275 Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With… Primary Membranous Nephropathy Recruiting
Phase 2
NCT07501702 A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Myasthenia Gravis, Generalized Recruiting
Sponsors Running Povetacicept Trials
Vertex Pharmaceuticals Incorporated (2) Alpine Immune Sciences Inc, A Subsidiary of Vertex (1)
Disease Areas
Myasthenia Gravis (1)
Get alerts when Povetacicept trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free